Loading
A phase 2 trial of Domvanalimab, Zimberelimab, Paclitaxel / nab-paclitaxel in head and neck squamous cell carcinoma, run by Gilead Sciences, active and no longer recruiting.
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 is a phase 2 interventional study registered as NCT06727565 by Gilead Sciences, with 39 participants enrolled, started 2025-02-18 and due to reach its primary completion in 2027-03. Interventions recorded: Domvanalimab, Zimberelimab, Paclitaxel, Carboplatin. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Domvanalimab, Zimberelimab, Gilead Sciences (incl. Kite), Carboplatin.
Shares Domvanalimab, Zimberelimab, Gilead Sciences (incl. Kite).
Shares Domvanalimab, Zimberelimab, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares Domvanalimab, Zimberelimab, Gilead Sciences (incl. Kite).
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma.
Shares Domvanalimab, Gilead Sciences (incl. Kite).
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma.
Shares Zimberelimab, Gilead Sciences (incl. Kite), Carboplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/